pyridine/diarrhea

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the national stage of International Application No. PCT/BE2007/000127, filed Dec. 14, 2007, which claims benefit of British Application No. GB 0624983.3, filed Dec. 14, 2006. FIELD OF THE INVENTION The present invention relates to a series

The present invention relates to compounds which potentiate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to compounds that are capable of modulating acetylcholine receptors.

The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,

The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,

The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders,

This application is a 371 of International Application No. PCT/IB2014/059817, filed 14 Mar. 2014, which claims priority of PCT/CN2014/072449, filed 24 Feb. 2014; PCT/CN2013/090059, filed 20 Dec. 2013; and PCT/CN2013/072683, filed 15 Mar. 2013. FIELD OF INVENTION This invention relates to novel

FIELD OF INVENTION The present invention is directed to modulators of the TGR5 receptor useful in the treatment of TGR5 mediated diseases or disorders. Specifically, the invention is concerned with compounds and compositions thereof, which activate the TGR5 receptor, methods of treating diseases or

FIELD OF THE INVENTION The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders,

BACKGROUND The vanilloid receptor 1 (VR1) is the molecular target of capsaicin, the active ingredient in hot peppers. Julius et al. reported the molecular cloning of VR1 (Caterina et al., 1997). VR1 is a non-selective cation channel which is activated or sensitized by a series of different stimuli

BACKGROUND The vanilloid receptor 1 (VR1) is the molecular target of capsaicin, the active ingredient in hot peppers. Julius et al. reported the molecular cloning of VR1 (Caterina et al., 1997). VR1 is a non-selective cation channel which is activated or sensitized by a series of different stimuli